Company profile
Seres Therapeutics, Inc.
NASDAQ: MCRB · Healthcare · Biotechnology
#891 of 1,418 Healthcare companies by revenue
EA Score
52DFH 55DQ 68GM 12SS 54
v0.1 · 65/100 weight · provisional
↑ net margin, return on equity · ↓ operating margin, growth stability
Methodology →Revenue TTM
$1.1M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$5.7M
Employees
66
as of 2026-08-18
Market cap
$42.7M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$789.0k$789.0k2025
Net income$5.7M$5.7M2025
Operating income-$94.0M-$94.0M2025
Total assets$138.2M$138.2M2025
Liabilities$94.0M$94.0M2025
Equity$44.2M$44.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY25
FY25
Revenue by segment
Filed disclosures · FY2019
By product
License And Service100%
By geography
Not disclosed.
The read
What is Seres Therapeutics, Inc.’s revenue?
Seres Therapeutics, Inc. booked $789.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a 721.9% net margin.
Peers · Healthcare
Helix BioMedix, Inc.56CImageneBio Inc48DBioCorRx Inc.44DHerborium Group, Inc.36DRising Biosciences, Inc.——Tivic Health Systems, Inc.34DNeighbors
Middlesex →Key facts
CEORichard N. Kender
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: MCRB
Employees66
IPO date2015-06-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.